Multiple Sclerosis and Related Disorders, Год журнала: 2024, Номер 92, С. 106173 - 106173
Опубликована: Ноя. 17, 2024
Язык: Английский
Biomolecules, Год журнала: 2025, Номер 15(3), С. 369 - 369
Опубликована: Март 4, 2025
Identifying reliable biomarkers in peripheral blood is critical for advancing the diagnosis and management of multiple sclerosis (MS), particularly given invasive nature cerebrospinal fluid (CSF) sampling. This review explores role B cells immunoglobulins (Igs), IgG IgM, as MS. cell oligoclonal bands (OCBs) CSF are well-established diagnostic tools, yet remain underdeveloped. Emerging evidence highlights structural functional variations immunoglobulin that may correlate with disease activity progression. A recent novel discovery aggregates MS patients fail to bind Protein reveals promising potential confirms previous findings unique features G link between superantigen These aggregates, enriched IgG1 IgG3 subclasses, exhibit properties, including mutations framework region 3 (FR3) IGHV3 genes, associated complement-dependent neuronal apoptosis. Data based on ELISA have demonstrated plasma can distinguish from healthy controls other central nervous system (CNS) disorders high accuracy differentiate subtypes. suggests a non-invasive monitoring.
Язык: Английский
Процитировано
0
Modern Pathology, Год журнала: 2025, Номер 38(8), С. 100770 - 100770
Опубликована: Апрель 11, 2025
Язык: Английский
Процитировано
0
Expert Opinion on Drug Safety, Год журнала: 2025, Номер unknown
Опубликована: Апрель 16, 2025
Monoclonal antibodies targeting CD20, such as rituximab, ocrelizumab, and ofatumumab, are crucial in managing multiple sclerosis (MS). However, they can cause hypogammaglobulinemia, increasing the risk of infections autoimmune disorders. This study describes cases hypogammaglobulinemia MS patients receiving anti-CD20 monoclonal antibodies, using data from European spontaneous reporting system database, EudraVigilance. A total 135 individual case safety reports (ICSRs), covering 469 adverse drug reactions (ADRs), were retrieved. The majority ICSRs related to ocrelizumab (N = 93) involved occurring adult females. Almost 20% reported concomitant medications, mainly represented by antibiotics, vitamins antiepileptics. Among ADRs, 36.8% serious, 66% had an unknown outcome. most commonly ADRs belonged SOC 'Infections infestations' included COVID-19 respiratory tract infection. Lastly, disproportionality analysis did not show a statistically significant probability gamma globulin reduction comparing each drug. highlights importance monitoring for occurrence ofatumumab rituximab MS. These be extremely serious highlight need ongoing research optimize their profiles.
Язык: Английский
Процитировано
0
Journal of Personalized Medicine, Год журнала: 2025, Номер 15(4), С. 155 - 155
Опубликована: Апрель 17, 2025
Background: B-cell-depleting drugs targeting the CD20 antigen have been increasingly implemented as an “exit strategy” from natalizumab for relapsing–remitting multiple sclerosis (RRMS) patients due to increased risk of progressive multifocal leukoencephalopathy. Data on recently approved anti-CD20 drugs, such ofatumumab serving a strategy”, are lacking. Furthermore, their immunosuppressive mechanism action, prolonged use these “highly effective” is associated with development hypogammaglobulinemia and, consequently, higher infections. There no guidelines monitoring serum immunoglobulin levels in individuals undergoing treatment. Methods: We present case 26-year-old male RRMS patient selective IgM deficiency and initially treated later ofatumumab. Results: The achieved “no evident disease activity “status while treatment ofatumumab, but therapies, especially greatly impacted further drops levels. However, significant decrease IgG was observed, infectious events occurred. In addition, did not show signs which also offered more convenient mode administration. Conclusions: Our experience points need explore benefit–risk ratios highly effective treatments, even cases low closely conducting clinical follow-ups ensure prompt recognition potential complications constitute approaches that thought patients.
Язык: Английский
Процитировано
0
Cells, Год журнала: 2025, Номер 14(8), С. 606 - 606
Опубликована: Апрель 17, 2025
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative autoimmune disorder of the central nervous system characterized by demyelination neurodegeneration. Traditionally considered T-cell-mediated disease, crucial role B lymphocytes in its pathogenesis, through different mechanisms contributing to inflammation autoreactivity, increasingly recognized. The risk long-term disability MS patients can be reduced an early treatment initiation, particular with high-efficacy therapies. aim this review provide overview action therapies for MS, focus on their impact cells how contributes drugs’ efficacy safety profiles. Anti-CD20 monoclonal antibodies, Alemtuzumab, Cladribine sequestering encompassing Natalizumab S1P receptors modulators will discussed emerging therapies, including Bruton’s Tyrosine Kinase inhibitors, presented.
Язык: Английский
Процитировано
0
IntechOpen eBooks, Год журнала: 2025, Номер unknown
Опубликована: Май 7, 2025
Therapeutic plasma exchange (PLEX) is a well-established therapy used for short- and long-term treatment of multiple sclerosis (MS), particularly patients with steroid-refractory relapses progressive disease subtypes. This chapter provides comprehensive overview the rationale, clinical evidence, best practices incorporating PLEX in difficult-to-treat MS. It explores mechanistic basis modulating immune responses outlines predictors response, including MRI findings timing initiation. Special attention given to pediatric populations underrecognized value maintenance Practical guidance vascular access, protocols, navigating insurance challenges also presented support clinicians specializing care MS who may benefit from PLEX.
Язык: Английский
Процитировано
0
Multiple Sclerosis and Related Disorders, Год журнала: 2024, Номер 93, С. 106191 - 106191
Опубликована: Ноя. 24, 2024
Язык: Английский
Процитировано
2
Meditsinskiy sovet = Medical Council, Год журнала: 2024, Номер 17, С. 58 - 65
Опубликована: Ноя. 7, 2024
Introduction. Multiple sclerosis (MS) is a chronic disease of the central nervous system predominantly affecting women reproductive age. It known that there high incidence low urinary tract infections in MS. However, information about microbiology genital with MS extremely limited. Aim. To study qualitative and quantitative composition vaginal microflora patients Materials methods. 19 relapsing-remitting main group healthy control group, secretion was determined using polymerase chain reaction method real time (a set reagents used to biocenosis urogenital women, Femoflor 16, DNA-Technology, Moscow), gynecological smear from vagina performed. The neurological status assessed EDSS scale questionnaire on pelvic organ function. following statistical indicators were determined: frequency, spread, average χ² test. Results. A normocenosis observed majority (14 subjects, 73.7%), Lactobacillus bacteria found 16 subjects (84.2%), an increased number facultative anaerobes identified 7 (37.4%), no significant differences comparator group. Bacteriological examination findings smears did not show any signs inflammation either anamnesis reported neurogenic lower dysfunction (16 84.2%). Conclusion. Data state has been presented for first time. preservation tendency shift balance towards dysbiotic processes vagina.
Язык: Английский
Процитировано
0
Опубликована: Ноя. 18, 2024
Язык: Английский
Процитировано
0
Multiple Sclerosis and Related Disorders, Год журнала: 2024, Номер 92, С. 106173 - 106173
Опубликована: Ноя. 17, 2024
Язык: Английский
Процитировано
0